Thrombotic Thrombocytopenic Pupura (TTP) - DAP A
NHS England
This tender has closed
The submission deadline for this contract has passed. There may be more active services tenders from NHS England, and hundreds more across the UK public sector.
Key details
Procurement
- 85100000 Health services
What happened
NHS England awarded this contract to Nottingham University Hospitals NHS Trust | Liverpool University Hospitals NHS Foundation Trust | The Newcastle upon Tyne Hospitals NHS Foundation Trust | Cambridge University Hospitals NHS Foundation Trust | Oxford University Hospitals NHS Foundation Trust | FindandTreat, University College London Hospital Foundation Trust | University Hospitals Bristol and Weston NHS Foundation Trust | University Hospital Birmingham NHS Foundation Trust | UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST | Sheffield Teaching Hospitals NHS Foundation Trust worth £552,301 on 16 Dec 2025.
Description
Thrombotic Thrombocytopenic Purpura (TTP) is a serious blood disorder with rapid onset, that results in blood clots forming in small blood vessels throughout the body. It affects the kidneys, heart and brain.
The condition can be difficult to diagnose because initial presentation can be non-specific, and this is a very rare disease. Rapid treatment is essential for optimal outcomes and includes plasma exchange and a range of drugs. This disease primarily affects adults. Children are treated in paediatric haematology centres with support from the adult specialists. Specialist aftercare is also required. Services are required to have a programme of outreach and education to improve timely diagnosis and referral. There is a small population with a congenital form of the disease who require ongoing treatment and monitoring.
Patients need to be able to access specialist care with 24/7 access to apheresis and a specialist team. Patients need to start in treatment within 4/8 hours of a referral to the specialist centre.
Full description
Thrombotic Thrombocytopenic Purpura (TTP) is a serious blood disorder with rapid onset, that results in blood clots forming in small blood vessels throughout the body. It affects the kidneys, heart and brain.
The condition can be difficult to diagnose because initial presentation can be non-specific, and this is a very rare disease. Rapid treatment is essential for optimal outcomes and includes plasma exchange and a range of drugs. This disease primarily affects adults. Children are treated in paediatric haematology centres with support from the adult specialists. Specialist aftercare is also required. Services are required to have a programme of outreach and education to improve timely diagnosis and referral. There is a small population with a congenital form of the disease who require ongoing treatment and monitoring.
Patients need to be able to access specialist care with 24/7 access to apheresis and a specialist team. Patients need to start in treatment within 4/8 hours of a referral to the specialist centre.
These contract awards have been made following direct award process A.
The estimated annual total value for this service is £13,782,927.
The contracts started on 1st April 2026 and the service will be incorporated into providers' main acute contracts.
Awarded suppliers (10)
- Nottingham University Hospitals NHS Trust
- Liverpool University Hospitals NHS Foundation Trust
- The Newcastle upon Tyne Hospitals NHS Foundation Trust
- Cambridge University Hospitals NHS Foundation Trust
- Oxford University Hospitals NHS Foundation Trust
- FindandTreat, University College London Hospital Foundation Trust
- University Hospitals Bristol and Weston NHS Foundation Trust
- University Hospital Birmingham NHS Foundation Trust
- UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST
- Sheffield Teaching Hospitals NHS Foundation Trust
Contact
Identifiers
Explore related tenders
Other tenders from NHS England
View all →External ID: fts-ocds-h6vhtk-068df7 • Added 29 April 2026